| A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer JP Neoptolemos, DD Stocken, H Friess, C Bassi, JA Dunn, H Hickey, ... New England Journal of Medicine 350 (12), 1200-1210, 2004 | 3296 | 2004 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2750 | 2020 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2235 | 2019 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1832 | 2012 |
| Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. N Bhala, J Emberson, A Merhi, S Abramson, N Arber, JA Baron, ... Lancet (London, England) 382 (9894), 769-779, 2013 | 1608 | 2013 |
| Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial JP Neoptolemos, JA Dunn, DD Stocken, J Almond, K Link, H Beger, ... The Lancet 358 (9293), 1576-1585, 2001 | 1324 | 2001 |
| COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study LYW Lee, JB Cazier, V Angelis, R Arnold, V Bisht, NA Campton, ... The Lancet 395 (10241), 1919-1926, 2020 | 1199 | 2020 |
| Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas C Palles, JB Cazier, KM Howarth, E Domingo, AM Jones, P Broderick, ... Nature genetics 45 (2), 136-144, 2013 | 1079 | 2013 |
| Genetic prognostic and predictive markers in colorectal cancer A Walther, E Johnstone, C Swanton, R Midgley, I Tomlinson, D Kerr Nature Reviews Cancer 9 (7), 489-499, 2009 | 966 | 2009 |
| A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24. 21 I Tomlinson, E Webb, L Carvajal-Carmona, P Broderick, Z Kemp, S Spain, ... Nature genetics 39 (8), 984-988, 2007 | 930 | 2007 |
| Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. DR Ferry, A Smith, J Malkhandi, DW Fyfe, PG deTakats, D Anderson, ... Clinical cancer research: an official journal of the American Association …, 1996 | 845 | 1996 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 796 | 2011 |
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 781 | 2005 |
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer G Hutchins, K Southward, K Handley, L Magill, C Beaumont, ... J Clin Oncol 29 (10), 1261-1270, 2011 | 774 | 2011 |
| Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial JP Neoptolemos, DD Stocken, JA Dunn, J Almond, HG Beger, P Pederzoli, ... Annals of surgery 234 (6), 758-768, 2001 | 721 | 2001 |
| A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23. 3 IPM Tomlinson, E Webb, L Carvajal-Carmona, P Broderick, K Howarth, ... Nature genetics 40 (5), 623-630, 2008 | 653 | 2008 |
| Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer R Salazar, P Roepman, G Capella, V Moreno, I Simon, C Dreezen, ... J clin oncol 29 (1), 17-24, 2011 | 645 | 2011 |
| A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma DH Palmer, RS Midgley, N Mirza, EE Torr, F Ahmed, JC Steele, ... Hepatology 49 (1), 124-132, 2009 | 641 | 2009 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 614 | 2020 |
| A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk P Broderick, L Carvajal-Carmona, AM Pittman, E Webb, K Howarth, ... Nature genetics 39 (11), 1315-1317, 2007 | 610 | 2007 |
Rachel Kerr (nee Midgley)University of OxfordAdresse e-mail validée de oncology.ox.ac.uk
